Balyasny Asset Management
RYTM icon

Balyasny Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Balyasny Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-52,967
Closed -$4.61M – 3432
2026
Q1 		$4.61M Sell
52,967
-19,315
-27% -$1.88M 0.01% 1394
2025
Q4 		$7.74M Sell
72,282
-277,726
-79% -$29.5M 0.01% 1164
2025
Q3 		$35.3M Buy
350,008
+295,920
+547% +$27.5M 0.04% 485
2025
Q2 		$3.42M Sell
54,088
-301,624
-85% -$18.5M 0.01% 1479
2025
Q1 		$18.8M Buy
355,712
+217,349
+157% +$12.1M 0.03% 623
2024
Q4 		$7.75M Buy
+138,363
New +$7.64M 0.01% 1081
2023
Q2 		– Sell
-16,313
Closed -$291K – 2729
2023
Q1 		$291K Buy
16,313
+15,547
+2,030% +$390K ﹤0.01% 2122
2022
Q4 		$22.3K Buy
+766
New +$19.7K ﹤0.01% 2471

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Balyasny Asset Management's RYTM Position: Q2 2026 in Review

Balyasny Asset Management sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2026, closing a stake of 52,967 shares — an estimated $4.61M sold.

Balyasny Asset Management first reported a position in RYTM in Q4 2022 and held it in 8 quarters. The position peaked at $35.3M in Q3 2025. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Balyasny Asset Management reported no remaining Rhythm Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 52,967 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $4.61M.
  • Balyasny Asset Management first reported a position in Rhythm Pharmaceuticals in Q4 2022 and held it in 8 quarters.
  • Balyasny Asset Management's Rhythm Pharmaceuticals position peaked at $35.3M in Q3 2025.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.